News
We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing ...
(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July ...
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.
Biotechnology company Veracyte (VCYT) is set to replace Triumph Group (TGI) in the S&P SmallCap 600 index prior to the market open on Tuesday, July 29.
View the latest Veracyte Inc. (VCYT) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners ...
Explore more
Shares of genetic diagnostics company Veracyte (VCYT-0.25%) are down 47% from their 52-week high of $86 set in February. Meanwhile, the S&P 500 is only down about 4% from its 52-week high set in ...
Veracyte VCYT has seen impressive growth over the past year, with its shares jumping 44%. It has significantly outperformed the industry ’s 3.9% rise and the S&P 500 composite’s 24.4% gain.
Veracyte's (NASDAQ:VCYT) Q3 2023 performance illuminates a company at a pivotal juncture in the genomic diagnostics arena. The financials reveal a robust 19% YOY revenue growth, ...
10d
Zacks Investment Research on MSNShould You Continue to Hold Veracyte Stock in Your Portfolio Now?
Veracyte VCYT is making solid progress in its long-term growth drivers, including in its NIGHTINGALE study for nasal swabs. The company’s Decipher franchise continues to be a strong tailwind, with ...
SOUTH SAN FRANCISCO, Calif.& PARIS---- Veracyte, Inc., a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a ...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results